Jörg M. StohrerSabine DittrichVonthalom ThongpaseuthViengxay VanisavethRattanaxay PhetsouvanhSamlane PhompidaFeliciano MontiEva Haria ChristophelNiklas LindegardhAnna AnnerbergTomas JelinekCharité – Universitätsmedizin BerlinCtr. MalariologyWHO Office Lao PDRThe World Health Organization Regional Office for the Western Pacific philippinesChurchill HospitalMahidol UniversityInstitute of Tropical Medicine2018-07-242018-07-242004-11-01Tropical Medicine and International Health. Vol.9, No.11 (2004), 1175-1183136022762-s2.0-9644287921https://repository.li.mahidol.ac.th/handle/123456789/21351The efficacy of the six-dose regimen of artemether-lumefantrine was compared with the combination of artesunate and mefloquine in a randomised, comparative trial in Luang Namtha Province, Northern Laos. Of 1033 screened patients, 201 were positive for Plasmodium falciparum; 108 patients of all age groups (2-66 years) with acute, uncomplicated P. falciparum malaria were enrolled in the study, 100 of whom were followed-up for 42 days. Fifty-three patients received artemether-lumefantrine and 55 received artesunante- mefloquine. Both drug combinations induced rapid clearance of parasites and malaria symptoms; there was no significant difference in the initial therapeutic response parameters. Both regimes were well tolerated. After 42 days, cure rates were 93.6% (95% CI = 82.5-98.7%; 44 of 47 patients) for artemether-lumefantrine and 100% (95% CI = 93.3-100.0%; 53 of 53 patients) for artesunate-mefloquine. The results show the excellent efficacy and tolerability of both artemether-lumefantrine and artesunate-mefloquine in Northern Laos.Mahidol UniversityImmunology and MicrobiologyMedicineArticleSCOPUS10.1111/j.1365-3156.2004.01320.x